XyloCor reveals promising 12-month data from Phase 2 Trial of XC001
XyloCor Therapeutics, a clinical-stage biopharmaceutical company focusing on novel gene therapies for cardiovascular diseases, has revealed encouraging 12-month data from the Phase 2 section of ... Read More